JPJagsonpal Pharmaceuticals507789Board meeting scheduled

Board meeting on 28 October 2026 to consider and approve unaudited results for September quarter

Board of Directors meeting scheduled for Wednesday, October 28, 2026.

By ScoutQuest · Wed 21 Oct 2026, 4:59 PM IST · 1 min read

Board Meeting Date

Wednesday, October 28, 2026

Agenda

Unaudited Financial Results (Standalone & Consolidated) for the quarter ended September 30, 2026

Trading Window Closure

closed till October 30, 2026

What was announced

• The Board of Directors of the company is scheduled to meet on Wednesday, October 28, 2026.
• The main item on the agenda is to consider and approve the Unaudited Financial Results, both Standalone and Consolidated, for the quarter ended September 30, 2026.
• The notice was addressed to BSE (Scrip Code: 507789) and NSE (Symbol: JAGSNPHARM).

Why standalone and consolidated matter

• Standalone results show the performance of the company on its own.
• Consolidated results include the company together with its subsidiaries or group entities, where applicable.
• Reading both together gives a fuller picture than either one alone.

Trading window

• The trading window for dealing in the company's securities will remain closed till October 30, 2026.
• This is a continuation of the company's earlier letter dated September 25, 2026 on closure of the trading window.
• The window is the period when designated persons connected with the company are restricted from trading in its shares around the time results are prepared and made public.

What to watch for

• The actual results, which will be considered and approved at the meeting, are the key event; this notice only sets the date.
• Once approved, the results are expected to be shared with the exchanges, and the numbers on revenue, profitability and segment-wise performance will be the ones to read.

What this notice is not

• It does not contain any financial figures, guidance or dividend proposal.
• It is an advance intimation of a board meeting, not the outcome of one.

Bottom line

• This is a routine scheduling disclosure that tells investors when the September quarter numbers will be taken up by the Board. The information that matters for investment decisions will come with the results themselves.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.

About ScoutQuest · Logos provided by Logo.dev